Key Sessions

Mark Farmery

Building an Industrialised Platform for the Development and Manufacture of Next-Generation T Cell Therapies

Anocca

Cristina Martinez Munoz

Manufacturing Excellence in cell therapy

Kite Pharma EU B.V.

Main Conference - Day 2Tuesday, 5 December 2023 - GMT (Greenwich Mean Time)

08:00 - 08:45

Morning Yoga

08:45 - 09:30

Coffee and Registration

Showing 1 of 1 Streams

Opening Keynote Plenary

09:30 - 09:40

Chairperson's Opening Remarks

Miguel Forte, MD, Ph.D. - President-Elect, International Society for Cell & Gene Therapy

09:40 - 10:20

Manufacturing Excellence in cell therapy

Kite, a Gilead Company, the leader in cell therapy
Manufacturing cell therapies: unique processes and challenges
Kite’s manufacturing network: delivering cell therapies to eligible patients across Europe and the World
Building on existing capabilities to meet increasing patient demand
Delivering innovative therapies in Europe: Barriers to access CAR T-cell therapy
Next chapter in commercializing cell therapies

Cristina Martinez Munoz - Senior Director Manufacturing, Kite Pharma EU B.V.

10:20 - 11:00

Morning Coffee and Networking Break in Exhibition & Poster Hall

Showing 3 of 3 Streams

Cell Therapy Manufacturing & Analytics

Gene Therapy Manufacturing & Analytics

CGT Partnering, Commercialization and Supply Chain

11:00 - 11:05

Chairperson's Opening Remarks

Leopold Bertea - Chief Technology Officer, Mendus AB

11:05 - 11:40

Building an Industrialised Platform for the Development and Manufacture of Next-Generation T Cell Therapies

Mark Farmery - Chief Development Officer, Anocca

11:40 - 12:15

Large-scale manufacturing of leukemic-derived dendritic cells as a basis for novel cancer immunotherapies

Leopold Bertea - Chief Technology Officer, Mendus AB

12:15 - 12:45

Considerations for biosafety testing of cell and gene therapies

Richard Adair - Senior Virology Manager, SGS

11:00 - 11:05

Chairperson's Opening Remarks

Jun Li - Associate Director, Upstream Process Development, Gene Therapy, Ultragenyx Pharmaceutical

11:05 - 11:40

Learnings from a cell therapy manufacturer on working with a CDMO to develop and establish a manufacturing process

Terri Gaskell - CTO, Rinri Therapeutics

11:40 - 12:15

Revolutionizing Cell and Gene Therapy: The Impact of Advanced Osmolality Testing on Process Development and Manufacturing

Kendal Studd - Field Application Specialist, Advanced Instruments

12:15 - 12:45

Streamlining AAV characterization with automated mass photometry

Perla Vega Dominguez - Technical Sales Specialist, Refeyn

11:00 - 11:05

Chairperson's Opening Remarks

Dan Stanton - Managing Editor, Bioprocess Insider, Informa Connect

11:05 - 11:40

Managing Durability of CGT: Communicating Value and Reducing Uncertainty

Ohad Karnieli, Ph.D., MBA - CEO, Adva Biotechnology
Miguel Forte, MD, Ph.D. - President-Elect, International Society for Cell & Gene Therapy

11:40 - 12:15

Navigating Partnership Challenges in CGT amid Changing Market Conditions

Eric Halioua - President & Chief Executive Officer, PDC*line Pharma
Thibault Jonckheere - CEO, Exothera
George Frodsham - CEO, MediSieve Limited

12:15 - 12:45

How to Optimise Reimbursement Strategies for CGT – Lessons Learned from Payers and Asset Holders

Brian Gavin - Strategy Director Europe, MAP Patient Access
Kevin McDonagh - Director & Country Manager, BioMarin Pharmaceuticals Inc.
Julie Adrian - Co-Founder & CEO, Alverium Health
Jim McGrath - Director of Commercial Policy, Irish Pharmaceutical Healthcare Association

Showing 2 of 2 Streams

Break

Live Labs

12:45 - 14:15

Lunch in the Exhibition & Poster Hall

13:30 - 13:40

Live Lab: QC requirements and support for biologics manufacturing

13:40 - 13:50

Live Lab: Maximise the efficiency of your cell and gene therapy shipments

Biocair understands the importance of your cell and gene therapy shipments. Join us at booth 508 where we will be demonstrating our packaging and the 24/7 advanced tracking solutions we offer, made especially with cell and gene therapy in mind.

Showing 3 of 3 Streams

Cell Therapy Manufacturing & Analytics

Gene Therapy Manufacturing & Analytics

CGT Partnering, Commercialization and Supply Chain

14:15 - 14:50

ProTcell: Manufacturing Challenges of T Cell Progenitor Based Therapy, A Phase III Strategy

Pierre Heimendinger - Chief Technical Officer, Smart Immune

14:50 - 15:20

Building Flexible End-to-End Cell Therapy Manufacturing Strategies

Luca Alberici - General Manager and Site Head, Cell and Gene Centre of Excellence, AGC Biologics

14:15 - 14:50

Next Generation bioreactors for manufacturing cell and gene therapies using Continues Adaptive Muli parameter control and AI to achieve increased quality, predictability and reproducibility.

Ohad Karnieli, Ph.D., MBA - CEO, Adva Biotechnology

14:50 - 15:20

ATMP Fluid Management and Freeze/Thaw

Brian Moloney - Director New Products & Innovation, Single Use Support

14:15 - 14:50

Partners with Purpose: Maximising the Value of Relationships within CGT

Best practices when working with CDMOs & CROs
Maximising the value of relationships with CDMO/CROs and Therapeutic Developer
Balancing research uncertainty and resource utilization – managing risks and choosing the right CDMO
An increasing focus on environmental, social, and governance (ESG) factors by stakeholders and consumers
Working together towards improved environmental & patient outcomes

Thibault Jonckheere - CEO, Exothera
Franck Toussaint - Executive Director & Co-Founder, Bio Supply Management Alliance Europe (BSMA Europe)
Eric Halioua - President & Chief Executive Officer, PDC*line Pharma

14:50 - 15:20

Please Move to Another Track

Showing 2 of 2 Streams

Break

Poster Sessions

15:20 - 16:00

Afternoon Coffee and Networking Break in Exhibition & Poster Hall

15:25 - 15:55

Poster Session in the Exhibit & Poster Hall

Check out our scientific poster hall and speak with the authors!

Showing 3 of 3 Streams

Cell Therapy Manufacturing & Analytics

Gene Therapy Manufacturing & Analytics

CGT Partnering, Commercialization and Supply Chain

16:00 - 16:35

Novel Analytical Technologies for Cell Therapy Product Characterisation Strategies

Monica Raimo - Senior R&D Manager, Glycostem Therapeutics

16:35 - 17:10

Case Study: Development of Potency Assays for Cell Therapies

Mahwish Natalia - Associate Director Cell Therapies, Takeda Oncology

16:00 - 16:35

Breaking Ground: Innovative Analytical Development for QC Assay Release in Decentralized Cell and Gene Therapy Product Manufacturing

Sagi Nahum - Senior Director – Analytical Sciences and CMC, Cell and Gene Therapy, Orgenesis

16:35 - 17:10

End of Track for Day 2 - Please Move to Another Track

16:00 - 16:35

Supply chain optimization of a CAR-T therapy

Hans-Peter Scherzer - Customer Success Project Manager, World Courier

16:35 - 17:10

Scaling Up Supply Chain to Meet Industry Objectives and Growth - Issues, Challenges, Opportunities, and Field Experience

Franck Toussaint - Executive Director & Co-Founder, Bio Supply Management Alliance Europe (BSMA Europe)

17:10 - 19:10

Networking Reception in Exhibition Hall

Main Conference - Day 2Tuesday, 5 December 2023 - GMT (Greenwich Mean Time)

Main Conference - Day 2Tuesday, 5 December 2023 - GMT (Greenwich Mean Time)

Get the Latest Event Updates